This is the authors' abstract. We don't add key points for this paper.
Preterm infants are highly susceptible to metabolic bone disease of prematurity (MBDP) due to insufficient accumulation of calcium and phosphate in their bodies caused by premature birth. Calcium supplementation can regulate bone calcium metabolism in preterm infants and promote their normal bone development, thus achieving the goal of treating or improving MBDP. However, currently available mineral supplements for the treatment of MBDP have limitations such as low bioavailability, gastrointestinal intolerance, induction of hyperfunction, and aluminum exposure. Casein phosphopeptides (CPPs) play a crucial role in calcium absorption and bone metabolism in preterm infants by efficiently binding to calcium ions. Based on a summary of the bone health of preterm infants, this article focuses on exploring the mechanism of calcium absorption promoted by CPPs and their mechanism of action in the bone metabolism of preterm infants, aiming to provide a theoretical basis for the prevention and treatment of MBDP and the expansion of mineral supplements.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: